Therapeutic effects of bone marrow-derived mesenchymal stem cells on radiation-induced lung injury

CHENGCHENG XIA1*, PENGYU CHANG1,2*, YUYU ZHANG3, WEIYAN SHI1, BIN LIU1, LIJUAN DING1, MIN LIU1, LING GAO1 and LIHUA DONG1

1Department of Radiation Oncology, The First Bethune Hospital of Jilin University, Changchun, Jilin 130000; 2 Key Laboratory of Radiobiology (Chinese Ministry of Health), School of Public Health, Jilin University, Changchun, Jilin 130000; 3 Department of Orthopaedics, The First Bethune Hospital of Jilin University, Changchun, Jilin 130000, P.R. China

Received July 20, 2015; Accepted September 17, 2015

DOI: 10.3892/or.2015.4433

Abstract. Radiation-induced lung injury (RILI) is a fatal condition featured by interstitial pneumonitis and fibrosis. Mesenchymal stem cells (MSCs) have been widely used for treating RILI in rodent models. In the present study, we aimed to investigate whether the therapeutic effects of human bone marrow-derived mesenchymal stem cells (hBM-MSCs) on RILI were in a dose-dependent manner. A total of 100 mice were randomly divided into: a control group (n=25), subject to lung irradiation and injection of phosphate-buffered solution (PBS) via the tail vein; and the groups (n=25), injected with PBS, low dose (1x10^3 hBM-MSCs/g), medium dose (5x10^3 hBM-MSCs/g), and high dose (1x10^4 hBM-MSCs/g) of hBM-MSCs in PBS through the tail vein, respectively. After sacrifice, the pulmonary tissues were subject to hematoxylin and eosin (H&E) staining, Masson's trichrome staining and immunohistochemical staining to investigate the pathological changes. Immunofluorescent staining was performed to evaluate the differentiation capacity of hBM-MSCs in vivo by analyzing the expression of SPC and PECAM. hBM-MSCs improved the survival rate and histopathological features in the irradiated mice, especially in the low-dose group. Marked decrease in collagen deposition was noted in the irradiated mice treated using a low dose of hBM-MSCs. In addition, hBM-MSCs attenuated secretion and expression of IL-10 and increased the expression of TNF-α. Furthermore, hBM-MSCs had the potential to differentiate into functional cells upon lung injury. Low-dose hBM-MSCs contributed to functional recovery in mice with RILI.

Introduction

Radiation-induced lung injury (RILI), in the form of pneumonitis and fibrosis, is fairly common in patients receiving thoracic radiation therapy. Unfortunately, the prognosis of patients with RILI is poor with a median survival time of less than 3 years (1,2). Currently, extensive studies have been conducted to investigate the relationship between cytokines and the pathogenesis of RILI (3,4). For example, overproduction of several cytokines appears to be related to the development of acute and late pulmonary toxicities after RILI, including pro-inflammatory cytokines such as interleukin-1α (IL-1α), IL-1β, interferon (IFN)-γ, IL-6, tumor necrosis factor α (TNF-α), and pro-fibrogenic cytokines such as transforming growth factor β1 (TGF-β1) and TGF-β (5-9).

Recently, accumulative evidence suggests that mesenchymal stem cells (MSCs), as gene therapy delivery vehicles, are involved in the repair of lung tissue damage by differentiating into functional cells and facilitating lung tissue regeneration by means of the generation of cytokines (10,11). For example, hepatocyte growth factor gene-modified MSCs contributed to the attenuation of RILI and inhibition of lung fibrosis (12). In addition, Asmussen et al (13) reported that human MSCs contributed to the improvement of oxygenation and attenuation of pulmonary oedema, especially in a high-dose group. Moreover, Devaney et al (14) revealed that a high dose of hMSCs was most effective in reducing E. coli-induced lung...
injury compared with a low-dose group. In the present study, we hypothesized that the therapeutic potential of bone marrow (BM)-derived MSCs on RILI may function in a dose-dependent manner. To this end, three different doses of hBM-MSCs were administrated in a mouse model of RILI to evaluate the therapeutic effects of different doses of hBM-MSCs in vivo. Our results revealed that low-dose hBM-MSCs contributed to functional recovery in mice with RILI.

Materials and methods

Cell culture. hBM-MSCs, kindly provided by the Cancer Center of the First Bethune Hospital of Jilin University (Changchun, China), were seeded into a flask with basal MSC medium supplemented with 5% fetal bovine serum (FBS), and 1% mesenchymal stem cell growth supplement (MSCGS) and 1% penicillin/streptomycin (Biowit Technologies, Shenzhen, China). Subsequently, the cells were cultured at 37°C with 5% CO₂ in a humidified atmosphere. Passaging was conducted every 2-3 days, and cells of passage 5 (P5) were used in the present study.

Animals. Mice (weighing 20±3 g) of the same genetic background were purchased from HFK Bioscience Co., Ltd. (Beijing, China). All animals were maintained under specific pathogen-free conditions, and had free access to water and a standard rodent diet provided by the Animal Center of Jilin University (Changchun, China). The study protocols were approved by the Animal Care and Use Committee of the Chinese Academy of Medical Sciences (Beijing, China).

Induction of RILI. To establish the RILI model, the whole lung was exposed to irradiation with a dose rate of 1,500 mGy/min using a low pass energy X-RAD 320 X-ray system (Precision X-ray, North Branford, CT, USA). The total dose was 18 Gy. The voltage was set at 300 kV, and the current was 11.79 mA.

Experimental design. A total of 100 mice were randomly divided into: i) a control group (n=25), which was subject to lung irradiation followed by injection of phosphate-buffered solution (PBS) via the tail vein; ii) a low-dose hBM-MSC group which was subject to lung irradiation followed by injection of 1x10³ hBM-MSCs/g in PBS through the tail vein; iii) a medium-dose hBM-MSC group which was subject to lung irradiation followed by 5x10³ hBM-MSCs/g through the tail vein; and iv) a high-dose hBM-MSC group which was subject to lung irradiation followed by 1x10⁴ hBM-MSCs/g through the tail vein. The delivery of hBM-MSCs was performed within 24 h after radiation.

Three mice randomly selected in each group were sacrificed under euthanasia on day 3, 7, 14, 28 and 84 after irradiation. Eye venous blood was collected to determine the cytokine levels using enzyme-linked immunosorbent assay (ELISA).

ELISA. Cytokine levels including HGF, IL-10 and TGF-β1, and Col were measured using standard ELISA kits purchased from R&D Systems (Minneapolis, MN, USA), eBioscience (San Diego, CA, USA) and USCN (Wuhan, China), according to the manufacturer's instructions.

Flow cytometry. Flow cytometry was carried out to determine the expression of cell-surface markers of the MSCs. Cells (P5) were fixed for 30 min in ice-cold 1% paraformaldehyde. Afterwards, the cells were stained at room temperature in the dark with the following primary mouse anti-human antibodies purchased from BD Biosciences (Franklin Lakes, NJ, USA): PE-conjugated CD11b, FITC-conjugated CD19, FITC-conjugated CD34, PE-conjugated CD45, PE-conjugated CD73, PE-conjugated CD90, PE-conjugated CD105 and PE-conjugated HLA-DR. FITC- or PE-conjugated mouse IgG1 served as the isotype control.

Tri-lineage differentiation. Cells (P5) were induced to differentiate into adipocytes, osteoblasts and chondrocytes using the StemPro® Adipogenesis differentiation kit, StemPro® Osteogenesis differentiation kit, and StemPro® Chondrogenesis differentiation kit (Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. The medium was replaced every 2-3 days. Approximately 21 days later, cell identification was performed by staining with Red Oil O, Alizarin Red and Aniline Blue, respectively.

Histological analysis. The left lungs were fixed using 10% neutral formalin for 8-10 h, followed by embedding with paraffin. Then the sections (4-µm) were subjected to hematoxylin and eosin (H&E) staining, Masson's trichrome staining and immunohistochemical staining, respectively. The images were evaluated by two qualified staff blinded to the details of this study using an Olympus BX51 microscope (Olympus, Tokyo, Japan).

Real-time PCR analysis. Total RNA was extracted from lung tissues using TRIzol (Invitrogen Inc., Carlsbad, CA, USA). The cDNA synthesis of TNF-α was performed using 1 µg RNA using M-MLV reverse transcriptase (Takara, Shiga, Japan). Real-time PCR amplification was carried out using SYBR on a Life 7500 Fast system (Life Technologies) with the following primers: TNF-α, 5'-ATCCgCgACgTggAACTg-3' and 5'-ACCgCCTgAgFTTCTgAA-3'; and β-actin, 5'-TGAGC TGGTTTTCACCCT-3' and 5'-AGGgTGGGgACTTCC TGTTAA-3'. PCR reactions were performed using a total of 20 µl containing 10 µl 2X SYBR Premix, 0.6 µl of each specific primer to a final concentration of 300 nM, and 1 µl cDNA template. PCR was performed under the following conditions: degeneration at 95°C for 15 min, followed by 40 cycles of denaturation at 95°C for 10 sec, annealing at 65°C for 30 sec and extension at 72°C for 30 sec. The mRNA level was normalized by β-actin. The amplification results were calculated as 2^-ΔΔCt according to a previous description (15).

Immunofluorescent staining. Immunofluorescent staining was performed to evaluate the tri-lineage differentiation capacity of hBM-MSCs in vivo by analyzing the expression of SPC and PECAM. In this section, 10 immunodeficiency mice were randomly divided into a non-irradiation + hBM-MSC group, subject to injection of 1x10³ hBM-MSCs/g in PBS through the tail vein; and a lung irradiation + hBM-MSC group, subject to lung irradiation followed by injection of 1x10³ hBM-MSCs/g in PBS through the tail vein. The animals were sacrificed 56 days after injection, and the left lung was collected. Subsequently,
the tissues were dewaxed in xylene and rehydrated with a gradient series of ethanol. Thereafter, the sections were incubated with the primary antibody against β2 microglobulin, SPC and PECAM at 4˚C overnight, followed by incubation with the secondary antibodies for 2 h at room temperature. The images were observed using PerkinElmer UltraView Vox confocal microscopy (PerkinElmer, Waltham, MA, USA).

Statistical analysis. Data are presented as the mean ± standard deviation. Statistical evaluation was performed using analysis of variance with a Tukey’s post hoc test. P<0.05 was indicative of a significant difference.

Results

Morphology and features of hBM-MSCs. Under in vitro conditions, hBM-MSCs are characterized by their spindle-like shape and clear cellular boundaries (Fig. 1A). In addition, hBM-MSCs show the capability of differentiating into adipocytes, osteoblasts and chondrocytes after culturing in defined medium (Fig. 1B-D). Cell-surface marker analysis showed that the hBM-MSCs represented a population of cells with expression of CD73, CD90 and CD105, and absence of hemapoietic markers such as CD11b, CD19, CD34 and CD45 (Fig. 1E).

Low-dose hBM-MSCs improve the survival rate and histopathological features in irradiated mice. The survival rate of animals in the hBM-MSC treatment groups was higher than the rate in the irradiation alone group. The survival rate of the mice in the low-dose MSC group was higher than that of mice in the high-dose group (Fig. 2A). For the histopathological results, RILI-associated features were initially observed on day 3 and were characterized by degradation of capillaries within alveolar septa and extravasation of erythrocytes into alveolar spaces (Fig. 2B). On day 28, alveolar structures with pathological lesions were observed in the lung with infiltration of inflammatory cells in the interstitial part and abnormal stromal hyperplasia. On day 84, infiltration of inflammatory cells and severe interstitial hyperplasia were observed. Compared with the control group, reduction in airspace inflammation and alveolar hemorrhage was observed in the groups treated with hBM-MSCs. In addition, the thickness of the interalveolar septa was modestly increased in the control.
hBM-MSCs decrease the collagen deposition in radiation lung injury. Masson staining on day 28 showed alveolar, bronchial, and vascular collagen deposition, which was increased on day 84 (Fig. 3A). Treatment of hBM-MSCs contributed to a decrease in collagen deposition in the radiation lung injury, especially in the low-dose group.

The expression of HGF and TGF-β1 in the stroma was aberrant after radiotherapy (Fig. 3B). After radiation, HGF expression was downregulated in blood vessels and bronchus. TGF-β1 was not expressed in normal lung tissues. Marked upregulation of TGF-β1 expression was noted in the radiation group; however, its expression was significantly decreased in the hBM-MSC groups compared with the radiation alone group.

HGF and TGF-β1 protein concentrations in peripheral blood were measured by ELISA (Fig. 3C and D). Serum TGF-β1 was reduced on day 28 and 84 after hBM-MSC interference. Compared with the non-treatment group, the serum HGF was increased after hBM-MSC interference on day 3, 7, 14, 28 and 84, respectively (P<0.05). Regarding Colla3 protein, the expression of Colla3 was downregulated in the lung tissue on day 84 after hBM-MSC interference compared with the control group (Fig. 3E). Among the hBM-MSC groups, the expression of Colla3 was significantly reduced in the low-dose group compared with the middle- and high-dose groups, respectively.

hBM-MSC therapy attenuates the secretion and expression of pro-inflammatory cytokines and improves the expression of anti-inflammatory cytokines. To evaluate the anti-inflammatory activity of hBM-MSCs, IL-10 was measured by ELISA in peripheral blood on day 3, 28 and 84 after radiation (Fig. 4A). The results indicated that hBM-MSCs significantly increased the expression of IL-10.

Real-time RT-PCR was used to detect the local inflammatory reaction of lung tissue on day 28 after radiation. Compared with the radiation group, hBM-MSCs reduced the expression of TNF-α mRNA (Fig. 4B).

hBM-MSCs differentiate into functional cells in the presence of lung injury. In order to prove the differentiation potential of hBM-MSCs, 10 immunodeficiency mice were divided into a non-radiation plus hBM-MSC (1x10^4 hBM-MSCs/g) group, and a lung irradiation plus hBM-MSC (1x10^4 hBM-MSCs/g) group, respectively. The epithelial cell markers, SP-C, and hBM-MSC marker, β2 microglobulin (β2-MG), were co-expressed in the lung irradiation plus hBM-MSC group (Fig. 5A). In addition, endothelial cell markers, PECAM and β2-MG, were co-expressed in the lung irradiation plus hBM-MSC group (Fig. 5B). In contrast, such markers were not expressed in the non-radiation plus hBM-MSC group. Taken together, the differentiation capacity of hBM-MSCs into functional cells only occurred in the presence of lung damage.

Discussion
In the present study, we hypothesized that the therapeutic potential of BM-MSCs on RILI may occur in a dose-dependent manner. Our results revealed that BM-MSCs could attenuate
RILI in mice compared with a control group. The survival rate of the mice in the low-dose MSC group was higher than that of mice in the high-dose group.

Previous studies have investigated the protective effects of clinical grade hMSCs under in vivo conditions using a low dose and a high dose, respectively. These results revealed that different doses of MSCs could exert protective effects in vivo compared with the control groups. Interestingly, the low-dose group was proven to be the more effective in improving the functional properties compared with the high-dose groups (13,16-19). In addition, a higher incidence of adverse events may occur in the high-dose group. For example, Li et al (20) showed that the
high-dose (1.0x10⁶ and 5.0x10⁵) groups induced lethal portal vein embolization (PVE) in mice with liver disease. On the contrary, no PVE and related death was observed in the low-dose (2.5x10⁵) group. Similarly, a low dose of MSCs showed greater safety and better therapeutic effects for RILI compared with the high-dose group. Compared with the control group, the hMSC treatment groups experienced alleviation of RILI, especially in the low-dose group.

To investigate the potential mechanism of the therapeutic effects of MSCs involved in RILI, we firstly assessed the expression of fibrosis-related factors TGF-β1, HGF and Col. TGF-β1, a major mediator involved in pro-inflammatory responses and fibrotic tissue remodeling, has been considered to play a crucial role in RILI (21). Meanwhile, inflammation may promote the expression of TGF-β1, forming a vicious circle in RILI. In the present study, the expression of TGF-β1 in the treatment groups was markedly downregulated compared with the irradiation group on day 28 and 84 after hBM-MSC interference, indicating that HBM-MSCs play important roles in the inhibition of fibrosis. HGF, associated with mitogenic, morphogenic and anti-apoptotic activities of BM-MSCs, was found to enhance the regeneration of the lung and to have an

Figure 4. Expression levels of pro-inflammatory and anti-inflammatory cytokines in peripheral blood and lung tissue. (A) A significant increase was noted in the levels of IL-10 in the hBM-MSC groups compared with the control group, especially in the low-dose group. *P<0.05 vs. radiation group; **P<0.01 vs. radiation group. (B) TNF-α mRNA expression was significantly decreased in the hBM-MSC groups compared with the control group. *P<0.05 vs. radiation group; **P<0.01 vs. radiation group. (A) High-dose (1.0x10⁶ and 5.0x10⁵) groups induced lethal portal vein embolization (PVE) in mice with liver disease. On the contrary, no PVE and related death was observed in the low-dose (2.5x10⁵) group. Similarly, a low dose of MSCs showed greater safety and better therapeutic effects for RILI compared with the high-dose group. Compared with the control group, the hMSC treatment groups experienced alleviation of RILI, especially in the low-dose group.

Figure 5. hBM-MSCs can differentiate into vascular endothelial cells and alveolar epithelial cells in the irradiated lung. (A) Double staining of CD34/β2-microglobulin (β2-MG). Blue color, cell nucleus; green color, alveolar epithelial cell marker SPC; red color, β2-MG. (B) Double staining of PECAM/β2-MG. Blue color, cell nucleus; green color, vascular endothelial cell marker PECAM; red color, β2-MG. The images were observed at a magnification of x400. Scale bars, 33 µm.
inhibitory effect on fibrosis (22). Wang et al (12) reported that Ad-HGF-modified MSCs improved histopathological and biochemical markers of RILI by attenuating the expression of inflammatory factors and fibrosis factors (e.g., TGF-β) and inhibiting fibrotic progression. In addition, compared with the non-transfected MSC group, Ad-HGF-modified MSCs contributed to the improvement of RILI by enhancing the release of endogenous HGF. Moreover, in a previous study, Kim et al (23) reported that MSC/HGF interference resulted in a significant reduction in liver fibrosis associated with elevated HGF levels and decreased TGF-β1 after MSC/HGF therapy. In the present study, a significant difference was noted in the expression of HGF after hBM-MSC interference compared with the control group on day 3, 14 and 28, especially the low-dose hBM-MSC group. Based on these results, we concluded that HGF plays an important role in the inhibition of fibrosis in RILI.

Next, we assessed the effects of BM-MSCs on inflammation-related factors such as TNF-α and IL-10. Previous studies revealed that murine MSCs could respond to pulmonary injury, reduce pro-inflammatory cytokines (IL-6 and TNF-α), collagen deposition and increase the expression levels of IL-10 and PGE2 (10,24-28). In addition, Lee et al showed that MSCs could restore alveolar fluid clearance, reduce inflammation, and exert antimicrobial activity partly through secretion of keratinocyte growth factors (29). In our study, hBM-MSCs appeared to be mediated by a shift from a pro-inflammatory response to RILI, and contributed to the alleviation of radioactive lung injury. Compared with the control group, downregulation of TNF-α and upregulation of IL-10 were observed in the BM-MSC group, especially the low-dose hBM-MSC group.

BMSCs have been reported to have the capacity to differentiate into various cell types, including endothelial cells, epithelial cells (30), adipocytes and osteocytes (31-33). In the present study, infrequent BM-MSC engraftment resulted in differentiation of BM-MSCs into epithelial cells and endothelial cells as revealed by double immunofluorescence staining. Furthermore, few MSCs were observed within the injured sites compared to tremendous loss of functional cells in the impaired tissues. Thus, we speculate that the tissue regeneration may not largely depend on direct differentiation of MSCs into functional cells. Considering the fact that therapeutic effects were observed even though heterogenic MSCs were rapidly cleared by the host after transplantation, we conclude that BM-MSCs facilitated tissue repair mainly through paracrine or autocrine actions.

In conclusion, a low dose of hBM-MSCs is superior to a high dose of hBM-MSCs with excellent safety and differentiation capacity in mice with RILI. We speculate that hBM-MSCs attenuate lung injury mainly via paracrine mechanisms, including upregulation of HGF and IL-10, as well as downregulation of TNF-α, TGF-β1 and Col-3. Thus, low-dose hMSCs may be a promising therapeutic approach for the management of RILI.

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (grant nos. 81272999 and 81372929).

References


